Below are the most recent publications written about "Thiophenes" by people in Profiles.
-
Ferrari LL, Ogbeide-Latario OE, Gompf HS, Anaclet C. Validation of DREADD agonists and administration route in a murine model of sleep enhancement. J Neurosci Methods. 2022 Oct 01; 380:109679.
-
Michelson AD, Smolensky Koganov E, Forde EE, Carmichael SL, Frelinger AL. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519.
-
Ramos-Espiritu L, Kleinboelting S, Navarrete FA, Alvau A, Visconti PE, Valsecchi F, Starkov A, Manfredi G, Buck H, Adura C, Zippin JH, van den Heuvel J, Glickman JF, Steegborn C, Levin LR, Buck J. Discovery of LRE1 as a specific and allosteric inhibitor of soluble adenylyl cyclase. Nat Chem Biol. 2016 10; 12(10):838-44.
-
Winkelman JW, Mackie SE, Mei LA, Platt S, Schoerning L. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. Sleep Med. 2016 08; 24:18-23.
-
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Apr 24; 350:h1857.
-
Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015 Apr 24; 350:h1585.
-
Spencer FA, Guyatt G. ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events. Ann Intern Med. 2015 Mar 17; 162(6):JC9.
-
Keaney JF. Balancing the risks and benefits of dual platelet inhibition. N Engl J Med. 2015 May 07; 372(19):1854-6.
-
Bu L, Dawson TJ, Hayward RC. Tailoring ultrasound-induced growth of perylene diimide nanowire crystals from solution by modification with poly(3-hexyl thiophene). ACS Nano. 2015 Feb 24; 9(2):1878-85.
-
Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ. VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2014 Jul; 26(7):761-73.